Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: Acetylcholinesterase activity cannot be considered a useful biomarker

Neurological Sciences

Volumn 34, Issue 5, 2013, Pages 769-771

  Antonelli, T ^a   Tomasini, M C ^a   Castellazzi, M ^a   Sola, P ^b   Tamborino, C ^a   Ferraro, D ^b   Ferraro, L ^a   Granieri, E ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b New Civil S Agostino Estense Hospital   (Italy)

Author keywords

Acetylcholinesterase; Axonal loss; Cerebrospinal fluid; Multiple sclerosis; Relapsing remitting

Indexed keywords

ACETYLCHOLINESTERASE; BIOLOGICAL MARKER;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CHOLINERGIC TRANSMISSION; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; FLUOROMETRY; HUMAN; INFLAMMATORY DISEASE; INTERMETHOD COMPARISON; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROPATHY; NONINFLAMMATORY NEUROLOGICAL DISORDER; OTHER INFLAMMATORY NEUROLOGICAL DISORDER;

ACETYLCHOLINESTERASE; ADULT; AXONS; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES;

EID: 84878018460     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-012-1265-9     Document Type: Article

References (16)

1. Compston A, Coles A (2002) Multiple Sclerosis. Lancet 359:1221-1231
2. Teunissen CE, Dijkstra C, Polman C (2005) Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 4(1):32-41
3. Prakash RS, Snook EM, Lewis JM, Motl RW, Kramer AF (2008) Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis. Multiple Scler 14(9):1250-1261
4. Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE, Krupp LB (2006) Effect of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci 245:127-136
5. Christodoulou C, MacAllister WS, McLinksey NA, Krupp LB (2008) Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option? CNS Drugs 22(2):87-97
6. Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE (2004) Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 63:1579-1585
7. Anglister L, Etlin A, Finkel E, Durrant AR, Lev-Tov A (2008) Cholinesterases in development and disease. Chem Biol Interact 175(1-3):92-100
8. Szelenki J, Bartha E, Hollán S (1982) Acetylcholinesterase activity from lymphocytes: an enzyme characteristic of T-cells. Br J Haematol 50:241-245
9. Gaspersic R, Horitnik B, Crne-Finderle N, Sketelj J (1999) Acetylcholinesterase in the neuromuscular junction. Chem Biol Interact 119-120:301-330
10. Silman I, Sussman J (2005) Acetylcholinesterase: "classical" and "non-classical" functions and pharmacology. Curr Opin Pharmacol 5:293-302
11. Kawashima K, Fujii T (2003) The lymphocytic cholinergic system and its biological function. Life Sci 72:2101
12. Tayebati SK, El-Assouad D, Ricci A, Amenta F (2002) Immunochemical and immunocytochemical characterization of cholinergic markers in human peripheral blood lymphocytes. J Neuroimmunol 132:147
13. Nizri E, Hamra-Amitay Y, Sicsic C, Lavon I, Brenner T (2006) Anti-inflammatory properties of cholinergic up-regulation: A new role for acetylcholinesterase inhibitors. Neuropharmacology 50:540-547
14. Virta JR, Laatu S, Parkkola R, Oikonen V, Rinne JO, Ruutiainen J (2011) Cerebral acetylcholinesterase activity is not decreased in MS patients with cognitive impairment. Multiple Scler 17(8):931-938
15. Marquis JK, Volicer L, Mark KA, Direnfeld LK, Freedman M (1985) Cholinesterase activity in plasma, erythrocytes, and cerebrospinal fluid of patients with dementia of the Alzheimer type. Biol Psychiatry 20:605-610
16. Steiner JM, Pirchl M, Ullrich C, Oberbauer H, Blasko I, Lederer W, Hinterhuber H, Humpel C (2008) Analysis of cerebrospinal fluid of Alzheimer patients. Pharmacology 82:214-220